ENZYCHEM LIFESCIENCES CORPORATION
Develops small molecule therapeutics for cancer, inflammation, and respiratory diseases.
183490 | KO
Overview
Corporate Details
- ISIN(s):
- KR7183490002
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 제천시 바이오밸리로 59, 제천시
- Website:
- https://www.enzychem.com/
- Sector:
- Manufacturing
Description
Enzychem Lifesciences Corporation is a biopharmaceutical company that develops novel small molecule therapeutics. The company's research targets fundamental pathways in inflammation to address significant unmet medical needs for patients with cancer, inflammatory diseases, and severe respiratory conditions. Its leading drug candidate, EC-18 (Mosedipimod), is a first-in-class oral small molecule derived from Sika deer antler. The clinical pipeline for EC-18 includes indications such as chemoradiation-induced oral mucositis (CRIOM), chemotherapy-induced neutropenia (CIN), acute radiation syndrome (ARS), and non-alcoholic steatohepatitis (NASH). The company also develops and manufactures Active Pharmaceutical Ingredients (APIs).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-16 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | HTML • 4.1 KB | ||
| 2021-12-03 00:00 |
기타경영사항(자율공시)(전환우선주(5우선주)_전환가액 조정)
|
Korean | HTML • 9.6 KB | ||
| 2021-12-03 00:00 |
[기재정정]주요사항보고서(유상증자결정)
|
Korean | HTML • 46.1 KB | ||
| 2021-12-03 00:00 |
[기재정정]증권신고서(지분증권) (2022.01)
|
Korean | HTML • 3.6 MB | ||
| 2021-12-02 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | HTML • 122.2 KB | ||
| 2021-11-24 00:00 |
[기재정정]주요사항보고서(유상증자결정)
|
Korean | HTML • 39.6 KB | ||
| 2021-11-24 00:00 |
[기재정정]증권신고서(지분증권) (2022.01)
|
Korean | HTML • 2.8 MB | ||
| 2021-11-22 00:00 |
투자판단관련주요경영사항(COVID-19 pDNA백신(ZyCoV-D) 제조라이선스기술이전 계약 체결)
|
Korean | HTML • 12.6 KB | ||
| 2021-11-16 00:00 |
[기재정정]증권신고서(지분증권) (2021.12)
|
Korean | HTML • 3.3 MB | ||
| 2021-11-15 00:00 |
분기보고서 (2021.09)
|
Korean | HTML • 2.0 MB | ||
| 2021-11-09 00:00 |
풍문또는보도에대한해명(미확정)
|
Korean | HTML • 6.9 KB | ||
| 2021-11-08 00:00 |
전환가액의조정
|
Korean | HTML • 12.2 KB | ||
| 2021-11-02 00:00 |
[기재정정]투자판단관련주요경영사항(항암화학방사선요법 치료를 받는 구강, 구인두, 하인두, 비인두 환자에게 유발되는 구강점막염에 대한 EC-18…
|
Korean | HTML • 14.5 KB | ||
| 2021-11-01 00:00 |
[기재정정]투자판단관련주요경영사항(항암화학방사선요법 치료를 받는 구강, 구인두, 하인두, 비인두 환자에게 유발되는 구강점막염에 대한 EC-18…
|
Korean | HTML • 15.4 KB | ||
| 2021-10-26 00:00 |
풍문또는보도에대한해명
|
Korean | HTML • 9.1 KB |
Automate Your Workflow. Get a real-time feed of all ENZYCHEM LIFESCIENCES CORPORATION filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ENZYCHEM LIFESCIENCES CORPORATION
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ENZYCHEM LIFESCIENCES CORPORATION via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
